519 related articles for article (PubMed ID: 27566651)
1. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Cancer Genomics Proteomics; 2016 09-10; 13(5):317-29. PubMed ID: 27566651
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and Therapy of Acute Myeloid Leukemia].
Medinger M; Heim D; Halter JP; Lengerke C; Passweg JR
Ther Umsch; 2019; 76(9):481-486. PubMed ID: 32157963
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia genomics.
Medinger M; Passweg JR
Br J Haematol; 2017 Nov; 179(4):530-542. PubMed ID: 28653397
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
5. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic options in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Leuk Res Rep; 2016; 6():39-49. PubMed ID: 27752467
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
8. [Acute leukemia in adults].
Eigendorff E; Hochhaus A
Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
[TBL] [Abstract][Full Text] [Related]
9. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
10. Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.
Nebbioso A; Benedetti R; Conte M; Iside C; Altucci L
Expert Opin Ther Targets; 2015; 19(9):1187-202. PubMed ID: 26028314
[TBL] [Abstract][Full Text] [Related]
11. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS; Pratz KW; Lai C
J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
[TBL] [Abstract][Full Text] [Related]
13. Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment.
Yamaguchi H
J Nippon Med Sch; 2022; 89(5):470-478. PubMed ID: 36351633
[TBL] [Abstract][Full Text] [Related]
14. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
15. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
17. Clinically useful prognostic factors in acute myeloid leukemia.
Ferrara F; Palmieri S; Leoni F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):181-93. PubMed ID: 17996460
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of acute myeloid leukemia.
Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
[TBL] [Abstract][Full Text] [Related]
19. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
20. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
Tallman MS
Hematology Am Soc Hematol Educ Program; 2005; ():143-50. PubMed ID: 16304372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]